Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor–Positive Pediatric Tumors
G Khanna, D Bushnell, MS O'Dorisio - The Oncologist, 2008 - academic.oup.com
In this paper, we review the pediatric oncologic applications of somatostatin receptor–
targeted imaging and therapy. Somatostatin receptors are expressed in high densities by …
targeted imaging and therapy. Somatostatin receptors are expressed in high densities by …
Poorly differentiated neuroendocrine tumors
JR Eads - Hematology/Oncology Clinics, 2016 - hemonc.theclinics.com
Poorly differentiated neuroendocrine carcinomas (NECs) are rare cancers with likely fewer
than 1000 cases diagnosed annually based on best estimates. 1, 2 Owing to its rarity, it has …
than 1000 cases diagnosed annually based on best estimates. 1, 2 Owing to its rarity, it has …
Integrating Functional Imaging and Molecular Profiling for Optimal Treatment Selection in Neuroendocrine Neoplasms (NEN)
G Kong, E Boehm, O Prall, WK Murray… - Current Oncology …, 2023 - Springer
Abstract Purpose of Review Gastroenteropancreatic NEN (GEP-NEN) are group of
malignancies with significant clinical, anatomical and molecular heterogeneity. High-grade …
malignancies with significant clinical, anatomical and molecular heterogeneity. High-grade …
Incidental cardiac findings on somatostatin receptor PET/CT: What do they indicate and are they of clinical relevance?
E Bobbio, A Dudás, A Bergström, D Esposito… - Journal of Nuclear …, 2022 - Elsevier
We present the case of a 47-year-old man with a history of recurrent episodes of frontal
headache, fever, and chest discomfort as well as longstanding, difficult to treat arterial …
headache, fever, and chest discomfort as well as longstanding, difficult to treat arterial …
[PDF][PDF] Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and …
Gastroenteropancreatic neuroendocrine tumors (GEPNETs) are a relatively rare,
heterogeneous group of diseases in which important advances have been observed in the …
heterogeneous group of diseases in which important advances have been observed in the …
Cardiac pheochromocytomas detected by Tc-99m-hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC) scintigraphy
L Chen, F Li, H Zhuang, H Jing, Y Du… - Clinical Nuclear …, 2007 - journals.lww.com
Primary pheochromocytomas of the heart are extremely rare tumors and difficult to diagnose.
Iodine labeled metaiodobenzylguanidine (MIBG) is the first choice of the nuclear medicine …
Iodine labeled metaiodobenzylguanidine (MIBG) is the first choice of the nuclear medicine …
State of the art and recent developments of radiopharmaceuticals for pancreatic neuroendocrine tumors imaging
A Carollo, S Papi, CM Grana, L Mansi… - Current …, 2019 - ingentaconnect.com
Background: Neuroendocrine Tumors (NETs) are relatively rare tumors, mainly originating
from the digestive system, that tend to grow slowly and are often diagnosed when …
from the digestive system, that tend to grow slowly and are often diagnosed when …
Методы ядерной медицины в диагностике нейроэндокринных опухолей
ДВ Рыжкова, ДН Тихонова… - Сибирский …, 2013 - cyberleninka.ru
Обзор литературы посвящен анализу радиофармацевтических препаратов (РФП) и
современных радиоизотопных технологий для диагностики, стадирования и оценки …
современных радиоизотопных технологий для диагностики, стадирования и оценки …
A Radioiodinated MIBG–octreotate conjugate exhibiting enhanced uptake and retention in sstr2-expressing tumor cells
G Vaidyanathan, DJ Affleck, J Norman… - Bioconjugate …, 2007 - ACS Publications
Several neuroendocrine tumors are known to express both the somatostatin receptor
subtype 2 (SSTR2) and the norepinephrine transporter (NET), and radiopharmaceuticals …
subtype 2 (SSTR2) and the norepinephrine transporter (NET), and radiopharmaceuticals …
Médecine nucléaire et imagerie multimodalités des tumeurs endocrines
M Calzada, I Keller, L Potier, V Gaura-Schmidt… - Médecine nucléaire, 2010 - Elsevier
Résumé Les tumeurs endocrines digestives (TED) ont une présentation clinique non
homogène par leur caractère sporadique ou familial, leur site embryologique, leur type …
homogène par leur caractère sporadique ou familial, leur site embryologique, leur type …